Moderna And Merck Say Their mRNA Cancer Vaccine Cut Death, Recurrence By 42%

TL;DR

Before you orderOffer from Amazon

Get everyday helpers delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

Moderna and Merck say their personalized mRNA vaccine, intismeran, combined with Keytruda reduced the two-year risk of melanoma recurrence or death by 42% compared with Keytruda and placebo. The companies reported improved recurrence-free and distant metastasis-free survival, but the supplied report does not include detailed safety results or a full peer-reviewed analysis.

Moderna and Merck said a personalized mRNA cancer vaccine, given with Merck’s Keytruda, reduced the two-year risk of melanoma recurrence or death by 42% compared with Keytruda and placebo in a Phase 3 trial. The findings concern patients with surgically removed melanoma and add late-stage evidence for a treatment designed around mutations in each patient’s tumor.

In the trial, 82% of patients who received intismeran, also known as mRNA-4157, plus Keytruda were alive without recurrence after two years. The corresponding figure was 70% in the Keytruda-and-placebo group. The companies described the 42% figure as a reduction in the risk of recurrence or death, not a 42-percentage-point increase in the share of patients who remained recurrence-free.

The companies also reported a 38% reduction in the risk of distant metastasis or death with the vaccine combination compared with Keytruda and placebo. At the reported endpoint, 88.5% of the combination group were alive without distant metastasis, versus 80% of the comparison group. Recurrence-free survival measures time without the cancer returning; distant metastasis-free survival measures time without its return at a different site, or death, as defined in the report.

Intismeran is designed using tumor-specific mutations. Researchers compare genetic sequences from a patient’s cancer and healthy cells, then select cancer-associated mutations for a synthetic mRNA vaccine that can encode up to 34 of them. The treatment is personalized rather than a single identical vaccine for every patient. The supplied report does not provide detailed adverse-event data, patient numbers or the full statistical analysis.

A Potential Advance After Melanoma Surgery

The results matter because the trial tested whether a personalized vaccine could improve outcomes after melanoma had been surgically removed, when treatment aims to reduce the chance that the disease returns or spreads. Keytruda was used in both groups, allowing the reported comparison to focus on adding intismeran to that treatment. The outcome measures reflect risks over time; they do not mean the vaccine prevents every recurrence or guarantees an individual patient’s survival.

If the findings are confirmed in a full analysis and accepted by regulators, the approach could add an option to post-surgery melanoma care. The reported figures are encouraging, but readers should distinguish a company announcement about trial results from a complete assessment of benefit, risks and suitability for particular patients. Treatment decisions require advice from qualified oncology professionals.

How the Vaccine Was Tested

The Phase 3 study compared intismeran plus Keytruda with Keytruda plus placebo in people with resected melanoma. Its main reported measures were recurrence-free survival and distant metastasis-free survival. These measures track whether and when cancer returns, rather than showing that all participants were cured.

The supplied report also places the new results alongside an earlier five-year Phase 2 trial. That study reported a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death. The newer Phase 3 estimates were smaller on both measures. Comparisons between trials need care because study populations, follow-up and methods can differ; the material provided does not give enough detail to explain the difference.

Merck Research Laboratories President Dean Li called the Phase 3 result a clinically meaningful improvement over standard-of-care Keytruda and said it set a new benchmark in the adjuvant setting. That is Merck’s characterization of the findings, not an independent regulatory conclusion.

“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.””

— Dean Li, president of Merck Research Laboratories

Details Await Full Trial Reporting

The supplied account is based on a company announcement and an Ars Technica report. It does not include the full Phase 3 data, study size, confidence intervals, statistical significance details, duration of follow-up beyond the reported two-year results, or a breakdown of side effects. Those details are needed to assess how robust the estimates are and to weigh potential benefits against harms.

It is also not clear from the material provided when the complete results will be published in a medical journal, whether regulators will review the data, or whether the vaccine will be authorized for this use. The reported risk reductions are group-level trial findings; they cannot establish an individual patient’s likely outcome.

Publication and Regulatory Review

The next steps to watch for are a full release of the Phase 3 results, including safety findings and statistical analyses, and any submission to health regulators. The supplied source material does not give a publication date, regulatory timetable or decision. Until those details emerge, the announced results should be read as promising trial findings rather than proof of approval or routine availability.

Further follow-up may also clarify whether the differences seen at two years persist over a longer period. Any decision about use would depend on the complete evidence and applicable regulatory review.

Key Questions

What does the reported 42% reduction mean?

The companies said the combination reduced the two-year risk of recurrence or death by 42% compared with Keytruda and placebo. It is a relative risk reduction, not a 42-percentage-point rise in the share of patients who remained recurrence-free.

What is intismeran?

Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed to encode selected mutations found in a patient’s tumor. The reported trial paired it with Keytruda.

Who was studied?

The results concern patients with resected melanoma—melanoma removed by surgery—who received Keytruda with either intismeran or placebo. The supplied material does not give further eligibility details.

Is the vaccine approved for this use?

The source material reports trial results but does not say that intismeran has been approved for this use or provide a regulatory decision timeline.

What information is still missing?

The full trial report, including participant numbers, detailed safety results and statistical analyses, was not included in the supplied material. Longer-term follow-up and any regulatory review also remain to come.

Source: hn